Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A 002399

Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026."We appreciate...